Latest news with #MolecularCancer
New York Post
6 days ago
- Health
- New York Post
Researchers make ‘significant discovery' in treating prostate cancer — what it means for patients
Looks like Ozempic isn't the only diabetes drug that wound up having a secret side hustle. A team of Swedish researchers has discovered that a drug traditionally meant for Type 2 diabetes shows immense promise in keeping prostate cancer at bay. A team of Swedish researchers has discovered that a drug traditionally meant for type 2 diabetes shows promise in keeping prostate cancer at bay. Peakstock – Advertisement The research — which was published in the journal Molecular Cancer — was based on studies on mice, as well as a retrospective study of 69 prostate cancer patients with type 2 diabetes, all of whom experienced a lack of cancer recurrence while using the drug. 'This is a significant discovery,' Lukas Kenner, a visiting professor at Sweden's Umeå University, said in a press release. Advertisement 'For the first time, we have clinical observations showing that prostate cancer patients with diabetes who received drugs targeting the protein [PPARy] remained relapse-free during the period we followed them.' Pioglitazone — a common anti-diabetic drug — not only slowed down the growth of cancer cells but also hampered their ability to grow back. 'The findings are very promising, but further clinical studies are needed to both confirm the results and to investigate whether the treatment can also be used in patients with prostate cancer who do not have diabetes,' Kenner said. It's the latest in a series of advances targeting prostate cancer — the second most common cancer among men in the US, after skin cancer. Advertisement 'This is a significant discovery,' Lukas Kenner said. jarun011 – A UCLA study found that an AI tool identified prostate cancer with 84% accuracy, compared to 67% by physicians, highlighting the potential of AI in improving diagnostic precision. A new at-home saliva test analyzes DNA for genetic markers associated with prostate cancer, offering a more accurate alternative to traditional blood tests and aiding in earlier detection. Advertisement And — following the shocking news that former President Joe Biden has an 'aggressive' form of prostate cancer — one Manhattan doctor is offering free PSA blood tests at his Midtown East office through the end of June. While the overall five-year survival rate for prostate cancer is as high as 97%, studies have shown that men who avoid prostate cancer screening appointments are 45% more likely to die from the disease.
Hans India
07-05-2025
- Health
- Hans India
Study shows diabetes drug may help treat prostate cancer
New Delhi: Certain drugs used to treat type 2 diabetes can also be used to treat prostate cancer, according to a study. Researchers from the Medical University of Vienna in Austria identified similarities in the mechanisms of diabetes and cancer. They showed that the protein PPARγ (peroxisome proliferator-activated receptor gamma) -- central to the regulation of metabolic processes -- can also influence the growth of prostate cancer cells. But PPARγ is already known to be a target of certain drugs including so-called thiazolidinediones such as pioglitazone, which are used to treat type 2 diabetes. The findings "showed that the diabetes drug pioglitazone influences the activity of PPARγ and thus inhibits the growth behaviour and metabolism of tumour cells. Furthermore, initial results revealed that prostate cancer patients with diabetes who were treated with PPARγ agonists had not relapsed at the time of data collection," explained Emine Atas from the Department of Biomedical Imaging and Image-guided Therapy at the varsity. The study, published in the journal Molecular Cancer, indicates that such drugs could slow down growth of prostate cancer cells, representing a promising approach for the treatment of prostate cancer. The researchers examined cell cultures and tissue samples from patient cohorts. They analysed how different activation states of the protein affect the cells. Prostate cancer occurs when abnormal cells in the prostate gland grow out of control. Despite enormous medical advances in recent years, prostate cancer is the most common cancer in men, with an estimated 1.4 million diagnoses and 375,000 deaths worldwide in 2020. The currently available treatment methods range from surgery and radiotherapy to medication. The identification of previously unknown molecular mechanisms could help to develop targeted therapies. PPARγ, as a potential regulator of tumour growth, is a promising option that will now be investigated in further studies, said the researchers.
